| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8225851 | International Journal of Radiation Oncology*Biology*Physics | 2012 | 8 Pages |
Abstract
Yttrium-90 therapy for hepatic neuroendocrine metastases leads to satisfactory tumor response and patient survival with low toxicity, in line with published national guidelines recommending radioembolization as a potential option for unresectable hepatic neuroendocrine metastases.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Khairuddin M.D., Robert J. M.D., Mary F. M.D., Ahsun M.D., Robert K. M.D., Kent T. M.D., Ramona M.D., Paul M.D., Frank H. M.D., Vahid M.D., Vanessa L. M.S., Bassel M.D., Steven M.D., Reed A. M.D., Al B. M.D., Riad M.D., M.B.A.,